Stephen Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Example of why having multiple agents is helpful.
Series of 12 patients with EGFR-mutant NSCLC who switched to lazertinib due to osimertinib toxicity (pulmonary, cardiac, hematologic).
Both 3G TKIs with similar efficacy but different toxicity profiles.”
Title: Osimertinib Toxicity Prompting Lazertinib Monotherapy: A Case Series
Authors: Neil Vaishampayan, Justin Jee, Jamie Chaft, Kathryn Arbour, Mark Kris, Gregory Riely, Rachel Rosenblum, Andrew Plodkowski, Helena Yu
Read the full article in JCO Precision Oncology.
You can also read:
